Vistin Pharma reports higher Q3 sales volume, despite lower metformin prices

Vistin Pharma ASA announced third-quarter 2025 revenues of MNOK 109, a 3% increase from MNOK 106 in Q3 2024, driven by a 10% rise in sales volume. Year-to-date revenue reached MNOK 342, up 8% from MNOK 316 in 2024. The company recorded an all-time high production volume of 1,600 MT of Metformin in the quarter.

Q3 2025 EBITDA stood at MNOK 28, a slight decrease from MNOK 29 in Q3 2024, attributed to lower global metformin prices offsetting the positive impact of higher sales volume. However, year-to-date EBITDA increased by 16% to MNOK 89 from MNOK 77 in 2024. Net profit for the third quarter was MNOK 18.5, compared to MNOK 16.6 in the same period last year. The company reported a net debt of MNOK 18 as of end September and maintained a gross margin of 68% in Q3, exceeding its long-term ambition of over 60%.

Vistin Pharma's strong balance sheet boasts an equity ratio of 74%. The company is strategically positioned in a growing diabetes market, with Metformin demand expected to increase by 4-6% annually. There have been no changes in customer demand following US tariff discussions, and Vistin continues to monitor for potential supply chain impacts.